Scalper1 News
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become a “hepatitis B virus therapeutics powerhouse” that could “create significant value for our shareholders,” said Tekmira CEO Mark Murray in the company’s statement. Tekmira was up more than 43% in midday Scalper1 News
Scalper1 News